Stock Analysis tagged as


  1. Finding Perfect Pullback Prices (SCLN, BRKR)

  2. 3 Hot Momentum Plays in a Cold Market (NVDA, AG)

  3. Take Advantage of Biotech's Bear Market Bounce (IBB, CELG)

  4. 3 Round Number Setups at 100

  5. Curb Your Enthusiasm With the Biotech Bounce

  6. 3 Low-priced Stocks Set to Head Higher

  7. 3 Plays for the Biotech Bear Market (GILD, UTHR)

  8. Zika Plays Ready to Break Out (XON, INO)

  9. Why Biotech Affimed N.V. Should Be On Your Radar (JUNO, AFMD)

  10. Roth Capital Reiterates Buy on Three Pharma Stocks

  11. Two Biotechs Worth A Look Ahead Of FDA Approvals (BDSI, SPPI)

  12. Analysts Bullish on BioDelivery Ahead of FDA Event (BDSI, ENDP)

  13. Analyst Bullish on Peregrine Following Q2 Update

  14. Analysts Bullish on OHR Pharma Amid Positive Study

  15. Celgene To Buy Receptos For $7.2B; Analysts Mixed

  16. Celgene's $1 Billion Deal to Fight Cancer

  17. Sarepta Therapeutics One Step Closer to Drug Approval

  18. OvaScience Releases Positive Data for Flagship Therapy

  19. The Future of 3D Printing in Biopharmaceuticals (ONVO, SSYS)

  20. Avian Flu Is Back: Is Inovio Now A Buy?

  21. The Best- and Worst-Performing Healthcare Stocks

  22. Investing In Biotech: Is It Worth The Risk?

  23. Biotechnology Stocks To Keep on the Radar

  24. Overlooked Israel Is A Portfolio Growth Engine

  25. Little Known Stocks And ETFs To Buy As Interest Rates Rise

  26. How To Hedge Your Grocery Bill- Higher Prices Are Coming

  27. Biotechnology: Some of the Strongest Stocks on Nearly Any Time Frame

  28. Vertex Building A Fortress In Cystic Fibrosis

  29. Does Amgen Deserve To Be Part Of The Biotech Bull Run?

  30. Pfizer Looking A Little Tired

  31. Celgene Only Getting Started, But The Street's Already Looking Ahead

  32. Amgen Puts Onyx Pharmaceuticals In Play

  33. A Summer Window Of Opportunity For Altera

  34. Alnylam Basking In Orphan Drug Attention

  35. Recent Financials May Not Be Entirely Fair To Hologic

  36. Amgen Chased By The Bubble

Trading Center